BRAF/+/melanoma patients exhibited higher 2‐year RFS rates in the entire cohort and the BRAF/MEK inhibitor‐treated group compared to those treated with anti‐PD‐1 antibodies. This evidence concerns the gene MAP2K7 and melanoma.